Brief: Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise For Treatment Of Multiple Myeloma
09/03/2022 12:08
March 9 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN PRESENTS NEW RESEARCH SUGGESTING TARGETING DNAM-1
AXIS
HOLDS PROMISE FOR TREATMENT OF MULTIPLE MYELOMA
* COMPUGEN LTD - DATA SHOW PVRIG IS MOST DOMINANT IMMUNE
CHECKPOINT IN THESE PATIENTS
Source text for Eikon: ID:nPn4SQzzJa
Further company coverage: CGEN.TA
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025